Moffitt Cancer Center

Name

Moffitt Cancer Center

Legal name

Moffitt Cancer Center

Website

https://moffitt.org

Company type

Private

Founded year

1981

Operating status

Operating

Headcount range

5,001–10,000 employees

Ownership category

akta.pro rank

Product category

Oncology Treatment & Research Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Ambulatory Health Care Services (621), General Medical and Surgical Hospitals (622110)

SIC

Services-Hospitals (8060), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industry

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)

Keywords

• Cancer treatment services
• Oncology research
• Clinical trials
• Cellular therapy
• Radiation oncology

Headquarters

HQ city

Tampa

HQ country

United States

HQ region

North America

Offices9 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Patient Care Services: Revenue generated from comprehensive cancer treatment services including surgery, chemotherapy, radiation therapy, immunotherapy, diagnostic services, and inpatient/outpatient care.
2. Research Grants and Sponsored Programs: Federal, state, and foundation grants funding cancer research activities, including collaborations with pharmaceutical and biotechnology companies for clinical trials.
3. Philanthropic Donations: Not-for-profit institution relying on donor support through the Moffitt Foundation for research advancement and facility expansion.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

Moffitt Cancer Center is a nonprofit, NCI-designated Comprehensive Cancer Center that diagnoses and treats more than 100 cancer types through an integrated care model spanning surgery, chemotherapy, radiation therapy, immunotherapy, precision medicine, and cellular therapies including CAR-T and TIL therapy. It also runs more than 400 clinical trials, conducts translational and basic cancer research, and operates multiple outpatient and inpatient facilities across Florida with virtual care and an online patient portal.

Product overview

Moffitt Cancer Center is a comprehensive cancer treatment institution offering integrated healthcare services across multiple modalities rather than a traditional software product company. The center operates a unified care delivery model combining diagnostic services, surgical care, radiation therapy, chemotherapy, immunotherapy, cellular therapies (including CAR T and TIL therapy), bone marrow transplant, precision medicine, and clinical trials. Patient access is facilitated through physical facilities across Florida, virtual care telemedicine services, an online patient portal, and genetic counseling programs. The institution's digital presence supports appointment scheduling, physician referrals, and health information access rather than functioning as a standalone software product.

Differentiator

Problem solved

Functional benefit

Brands

• Moffitt Medical Group: Florida's largest multispecialty medical group practice dedicated to cancer treatment
• Moffitt Cancer Center Speros
• Speros Powered by Moffitt

Products and services

• Clinical Trials Program Conducts more than 400 clinical trials across cancer types, providing patients access to novel treatments including immunotherapy, targeted therapy, and cellular therapies before widespread availability.
• Blood and Bone Marrow Transplant and Cellular Immunotherapy FACT-accredited bone marrow and stem cell transplant program with cellular therapy capabilities for blood cancers and hematologic malignancies.
• CAR-T Cell Therapy Chimeric antigen receptor T-cell therapy program treating blood cancers using patient-derived engineered immune cells.
• TIL Therapy (Tumor-Infiltrating Lymphocyte) Cellular immunotherapy using tumor-infiltrating lymphocytes extracted from patient tumors and expanded for therapeutic use.
• Immunotherapy Program Comprehensive immunotherapy treatments including checkpoint inhibitors, CAR-T, TIL therapy, and novel immunomodulatory agents for cancer patients.
• Radiation Therapy Advanced radiation oncology services including proton therapy at the Richard M. Schulze Family Foundation Proton Therapy Center, IMRT, and stereotactic radiosurgery.
• Diagnostic Services Comprehensive diagnostic capabilities including advanced imaging (PET-CT, MRI, CT), laboratory services, genetic testing, and digital pathology.
• Precision Medicine Personalized cancer treatment approach using genomic profiling, molecular testing, and targeted therapies matched to individual tumor characteristics.
• Surgical Care Surgical oncology procedures including minimally invasive, robotic, and complex cancer surgeries across all tumor types.
• Chemotherapy Systemic chemotherapy administration including traditional cytotoxic agents and novel chemotherapeutic combinations.
• Moffitt Virtual Care Telemedicine and virtual visit services connecting Florida-based patients with cancer experts through video appointments for consultations and follow-up care.
• Genetic Counseling and Testing Hereditary cancer risk assessment, genetic testing, and counseling services for patients and families.
• Cancer Screenings Early detection services including mammography, lung cancer screening, colonoscopy, and head/neck cancer screening programs.
• MyMoffitt Patient Portal Online patient portal for accessing medical records, scheduling appointments, messaging care teams, and managing health information.

Quantifiable outcome

• Patient satisfaction rating of 4.9 out of 5 based on 66,279 reviews
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature5 records

Partnerships

16 partnerships are on record, tiered core and minor.

• Foundation MedicinecoreStrategic or Co-development Partner · 31 July 2023Foundation Medicine awarded a grant to Moffitt Cancer Center and LUNGevity to support efforts in removing barriers to information about personalized oncology for Black patients, addressing health equity in cancer care.
• Anixa BiosciencescoreStrategic or Co-development PartnerCollaboration on CAR-T therapy (lira-cel) for ovarian cancer and breast cancer vaccine development. Moffitt serves as clinical trial site for Phase 1 studies.
• RenovoRxcoreStrategic or Co-development PartnerMoffitt Cancer Center published peer-reviewed case study demonstrating successful use of RenovoRx's TAMP platform via RenovoCath for intra-arterial chemotherapy delivery in pancreatic cancer.
• Dicom SystemscoreTechnology or IntegrationPartnership to support and scale Moffitt's digital pathology infrastructure using the Unifier Platform, enabling faster case review and second opinions across locations.
• PathAIcoreTechnology or IntegrationMulti-year strategic collaboration to deploy PathAI's FDA-cleared AISight Dx digital pathology platform across Moffitt's pathology programs for AI-powered cancer diagnostics.
• TakedacoreStrategic or Co-development PartnerResearch Alliance with Takeda to advance cancer therapies, expanding clinical and translational research in blood cancers and solid tumors.
• RyboDynminorStrategic or Co-development PartnerRyboDyn collaborates with Moffitt Cancer Center on drug discovery efforts using its proprietary CypherAtlas database targeting the dark proteome for cancer treatment.
• Rad AIcoreStrategic or Co-development PartnerResearch collaboration on domain-specific AI models for radiology, training on over 500 million radiology reports. Study published in npj Digital Medicine found radiologists prefer domain-specific AI over generic AI.
• BioLineRx and HemispherianminorStrategic or Co-development PartnerPhase 1/2a clinical trial of GLIX1 for glioblastoma being conducted at NYU Langone Health, Northwestern University, and Moffitt Cancer Center.
• BullFrog AIminorStrategic or Co-development PartnerCollaboration with BullFrog AI on biomarker analysis of pancreatic cancer trial data using the bfLEAP platform, identifying patient subgroups with improved survival outcomes.
• Trinity College DublinminorStrategic or Co-development PartnerJoint research with Trinity College Dublin on evolutionary double-bind strategy using radiation therapy followed by NK cell immunotherapy for metastatic cancer.
• spARK Labs by ARK InvestminorStrategic or Co-development PartnerPartnership to work with early-stage oncology AI companies, with Moffitt experts moving into the innovation facility. Collaboration aimed at advancing AI-powered solutions in oncology and life sciences.
• Memorial Healthcare SystemcoreStrategic or Co-development PartnerEstablished partnerships with Memorial Healthcare System for diagnosis, treatment, and support services. Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System location.
• AdventHealthcoreStrategic or Co-development PartnerPartnership with AdventHealth for delivery of diagnosis, treatment, and support services to patients in the Tampa Bay area.
• University of South FloridacoreStrategic or Co-development PartnerMoffitt's research facilities are located primarily within the University of South Florida campus. Collaborative research and academic partnership in cancer research and training.
• Cleveland CliniccoreStrategic or Co-development PartnerAnixa Biosciences collaboration with both Moffitt Cancer Center and Cleveland Clinic on breast cancer vaccine and CAR-T therapy development.

Scale indicators6 records

Recent moves9 records

Expansion highlights4 records

Direct peers

• Dana-Farber Cancer Institute: Dana-Farber is an NCI-designated Comprehensive Cancer Center affiliated with Harvard, offering the same integrated research, clinical trials, and specialty oncology care as Moffitt, with a comparable focus on cellular therapies and precision medicine.
• Mayo Clinic Comprehensive Cancer Center: Mayo Clinic's NCI-designated cancer center operates a similar destination-medicine model combining multispecialty clinical care, translational research, and a large clinical trials portfolio, with significant overlap in CAR-T, proton therapy, and hematology-oncology offerings.
• Cleveland Clinic (Taussig Cancer Center): Cleveland Clinic's Taussig Cancer Institute is an NCI-designated Comprehensive Cancer Center with parallel inpatient, outpatient, cellular therapy, and clinical trial capabilities. Moffitt is already a co-development partner with Cleveland Clinic on Anixa's CAR-T program, confirming operational overlap.
• Memorial Sloan Kettering Cancer Center: MSK is one of the oldest and largest NCI-designated Comprehensive Cancer Centers, operating a parallel model of inpatient cancer hospital, outpatient network, and translational research — directly comparable to Moffitt in scope, NCI designation, and trial-driven patient acquisition.
• Fred Hutchinson Cancer Center: Fred Hutchinson (now Fred Hutchinson Cancer Center) is an NCI-designated facility with deep expertise in bone marrow transplant and cellular immunotherapy, overlapping with Moffitt's FACT-accredited BMT and CAR-T programs.
• Johns Hopkins Sidney Kimmel Comprehensive Cancer Center: Johns Hopkins Kimmel is an NCI-designated Comprehensive Cancer Center combining academic research, multispecialty oncology care, and large clinical trial enrollment — a near-direct structural peer to Moffitt in the academic medical center cancer model.
• MD Anderson Cancer Center: The University of Texas MD Anderson Cancer Center is the largest NCI-designated Comprehensive Cancer Center in the U.S. and the most direct peer to Moffitt — same regulatory designation, same inpatient hospital and outpatient model, similar 100+ cancer type coverage, and overlapping clinical trial and research missions.
• UCSF Helen Diller Family Comprehensive Cancer Center: UCSF's NCI-designated cancer center offers the same integrated research, precision medicine, and clinical trials structure as Moffitt, with notable strength in immunotherapy and cellular therapy — directly comparable on translational research depth.
• Winship Cancer Institute of Emory University: Winship is the only NCI-designated Comprehensive Cancer Center in Georgia, operating the same academic-medical-center cancer model as Moffitt with comparable research, clinical trial, and specialty oncology services.

Regional players

• Sylvester Comprehensive Cancer Center (University of Miami): Sylvester is the other NCI-designated Comprehensive Cancer Center in Florida, competing with Moffitt for in-state patients, clinical trial enrollment, and biopharma partnerships within the same regional market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/MoffittNews
• Facebookfacebook.com/MoffittCancerCenter
• LinkedInlinkedin.com/company/moffitt-cancer-center

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries6 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Moffitt Cancer Center